



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Weber et al.
Application No.: 10/590,391
Filed: August 23, 2006
For: PHARMACOLOGICALLY
ACCEPTABLE SALTS OF
CLOPIDOGREL

Examiner: Unassigned
Group Art Unit: Unassigned
Docket: 753-71 PCT/US
Dated: January 31, 2007

Confirmation No.: Unassigned

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, address to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 31, 2007

Signature: Barbara Thomas

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98. The documents are listed on PTO Form 1449. We have enclosed the cited documents, except for the cited U.S. Patent as the U.S. Patent Office has waived paper submission thereof, to facilitate reference to them.

Each item of information contained in this Information Disclosure Statement was first cited in an International Search Report from a foreign patent office in the corresponding International Application No. PCT/CH2005/000086. A copy of the International Search Report

Applicant: Weber et al.
Application No.: 10/590,391
Filing Date: August 23, 2006
Docket No.: 753-71 PCT/US
Page 2


is enclosed for the convenience of the Examiner. The Search Report indicates the degree of relevance found by the foreign office, and thus, is submitted in accordance with MPEP §609. Except as being cited in the above-mentioned reports, the exact relevance of certain references is unknown.

Since this Information Disclosure Statement is being submitted before the issuance of a first Office Action, no fee is believed to be necessary. If, however, a fee is necessary, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-2461.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R. § 1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. § 1.136.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,


Jamie M. Larriann
Registration No.: 48,623
Attorney for Applicants

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
753-71 PCT/USSERIAL NO.
10/590,391INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Weber et al.CONFIRMATION NO.
Unassigned

(Use several sheets if necessary)

FILING DATE
August 23, 2006GROUP
Unassigned

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	4,847,265	07-11-89	Badorc et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	WO99/6591 5 A	12-23-99	PCT				
	WO2004/07 2084 A	08-26-04	PCT				
	WO2004/07 2085 A	08-26-04	PCT				
	WO2004/10 6344 A	12-09-04	PCT				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

EXAMINER

/Niloofer Rahmani/

DATE CONSIDERED

02/17/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 753-71 PCT/US	SERIAL NO. 10/590,391
	APPLICANT Weber et al.	CONFIRMATION NO. Unassigned
	FILING DATE August 23, 2006	GROUP Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Caira, M. R., "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, Vol. 198, pp. 163-208 (1998)
			Savi, P., et al., "Clopidogrel: A Review of its Mechanism of Action", Platelets (Edinburgh), Churchill Livingstone Medical Journals, GB, Vol. 9, No. 3/4, pp. 251-255 (1998)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

EXAMINER

/Niloofer Rahmani/

DATE CONSIDERED

02/17/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.